Refers to piperidiniltetrahidroquinolinas substituted Derivatives of formula (i) wherein R1, R2, R3 and R4 are as defined in the description.Preferred compounds are: [4 - (4 - dihidroisoquinolin - 2 (1H) - il) piperidin-1-yl] [2 - (6 - [3 - azaespiro Oxa.3] hept-3-ene - 6 - il) pyrimidin-5-yl] methanone [4 - (7 - fluoro - 3.4 - dihidroisoquinolin - 2 (1H) - il) piperidin-1-yl] [2 - (oxa - 6 - azaespiro [3.3] hept-3-ene IL - 6 - pyrimidin-2-yl) - 5 - il] methanone among others.It also relates to a preparation method and a Pharmaceutical composition.These compounds are antagonists of alpha adrenergic receptor 2C being useful for the treatment of diabetic microangiopatias thromboembolic DisordersSE REFIERE A DERIVADOS DE PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS DE FORMULA (I) DONDE R1, R2, R3 Y R4 SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: [4-(3,4-DIHIDROISOQUINOLIN-2(1H)-IL)PIPERIDIN-1-IL][2-(2-OXA-6-AZAESPIRO[3.3]HEPT-6-IL)PIRIMIDIN-5-IL]METANONA [4-(7-FLUORO-3,4-DIHIDROISOQUINOLIN-2(1H)-IL)PIPERIDIN-1-IL][2-(2-OXA-6-AZAESPIRO[3.3]HEPT-6-IL)PIRIMIDIN-5-IL]METANONA ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR ADRENERGICO ALFA-2C SIENDO UTILES PARA EL TRATAMIENTO DE MICROANGIOPATIAS DIABETICAS, TRASTORNOS TROMBOEMBOLICOS
